bamlanivimab monotherapy - versus control - for COVID-19 prophylaxis (excluding childrens) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.83 [0.25, 2.73]< 10%1 study (1/-)62.1 %some concernnot evaluable moderatecrucial-
infection (PCR positive symptomatic or not) 0.43 [0.28, 0.67]< 10%1 study (1/-)100.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

adverse events 2.02 [1.54, 2.64]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.